Navigation Links
Roche Files IND for Second Genmab Antibody
Date:12/20/2007

Summary: Genmab's Partner Roche has Filed an IND With the US FDA for a

Genmab Antibody

COPENHAGEN, August 10 /PRNewswire-FirstCall/ -- Genmab A/S (OMX: GEN) announced today that its partner Roche has filed an Investigational New Drug application (IND) with the US Food and Drug Administration for a Genmab antibody developed under the companies' collaboration. Genmab will receive a milestone payment from Roche which does not influence Genmab's financial guidance for 2007.

Under the agreement with Roche, Genmab utilizes its broad antibody expertise and development capabilities to create human antibodies to a broad range of disease targets identified by Roche. Genmab receives milestone and royalty payments based on successful products. In certain circumstances, Genmab may obtain rights to develop products based on disease targets identified by Roche. If all goals are reached, the value of the collaboration to Genmab could be USD 100 million, plus royalties.

"This will be the second antibody produced under our collaboration with Roche to enter the clinic and Genmab's seventh antibody to enter clinical development overall," said Lisa N. Drakeman, Ph.D., Chief Executive Officer of Genmab. "Our partnership with Roche continues to bear fruit and add value to Genmab's expanding product pipeline."

About Genmab A/S

Genmab is a leading international biotechnology company focused on developing fully human antibody therapeutics for unmet medical needs. Using unique, cutting-edge antibody technology, Genmab's world class discovery and development teams have created and developed an extensive pipeline of products for potential treatment of a variety of diseases including cancer and autoimmune disorders.

As Genmab advances towards a commercial future, we remain committed to our primary goal of improving the lives of patients who are in urgent need of new treatment options. For more information on Genmab's prod
'/>"/>

SOURCE Genmab A/S
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Roche Joins Forces With Enon Tabernacle Baptist Church to Provide Free Hepatitis C Testing to the Community
2. Roche Extends Tender Offer for Ventana
3. Pharmasset and Roche to Present R7128 Data at the 14th International Symposium on Hepatitis C Virus and Related Viruses
4. Roche Real-Time HIV Test is Faster and Less Labor-Intensive Than Competitors
5. Indivumed Supports Roche Diagnostics With Immunohistochemistry Services and Clinical Specimens for Biomarker Discovery and Drug Development
6. Amarin Announces Publication of Pre-Clinical Memory Data in Journal of Neurochemistry
7. Med Ad News Honors Roche as Company of the Year
8. MacroChem To Participate in PIPEs Conference October 18th and 19th in New York City
9. MacroChem Announces Michael Zasloff, M.D., Ph.D. Joins Companys Scientific Advisory Board
10. Phase I Results Announced for R1507 From Genmabs Collaboration With Roche
11. Kosan to Reacquire Epothilone Program From Roche
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/17/2013)... BOSTON , June 17, 2013 ... $127 billion by 2018, accounting for nearly 16 percent of ... Orphan Drug Report 2013 from Evaluate .   ... to this growing segment of the pharmaceutical industry, Evaluate has ... in-depth, fact-based orphan drug analysis with data fields for integrated ...
(Date:6/17/2013)... 2013 With the huge success of CMO ... Chief Medical Officer Summit for Emerging Life Science Companies on ... in San Francisco on November 4-5, 2013 at the Marines ... West Coast Chief Medical Officers at biotechs have their own ... Director of MPM Capital. Valerie Bowling, Executive Director of The ...
(Date:6/17/2013)... Z Trim Holdings, Inc. (OTC Markets: ... ingredients to a variety of industries, today announced ... application at this year,s annual Institute of Food ... , July 13-16. The Company will demonstrate how ... in meat products thereby helping manufacturers lower costs ...
(Date:6/17/2013)... , June 17, 2013 ... ) has announced the addition of the ... - by Formulations [Liposomes, Microspheres, & Nanoparticles], ... Pen, Needle Free & Auto Injectors] & ... their offering. ,      (Logo: ...
Breaking Biology Technology:Evaluate Launches Enhanced Orphan Drug Intelligence 2Evaluate Launches Enhanced Orphan Drug Intelligence 3Chief Medical Officer Summit for Biotechs Goes West 2Chief Medical Officer Summit for Biotechs Goes West 3Z Trim to Spotlight New Meat Applications at IFT 2013 in Chicago 2Z Trim to Spotlight New Meat Applications at IFT 2013 in Chicago 3North America Injectable Drug Delivery Market - by Formulations, Devices & Therapeutics- Forecasts to 2017 2North America Injectable Drug Delivery Market - by Formulations, Devices & Therapeutics- Forecasts to 2017 3
... adds new line of heart disease and diabetes ... 20 Atherotech, Inc. ... Cholesterol Test in booth #912 at Internal Medicine ... College of Physicians (ACP). The conference takes place ...
... Proof of Mechanism of a Potential Oral Antagonist for ... Amira Pharmaceuticals, Inc., announced today the initiation of ... discovered oral drug candidate for the treatment and control ... acid pathway.AM211 is an oral, selective antagonist of the ...
... Data are New Releases for the Company Building ... Discoveries --DENVER, April 20 DXL625 ... antibodies in their ability to attach and deplete ... research conducted at InNexus Biotechnology Inc. (Toronto Stock ...
Cached Biology Technology:Atherotech to Exhibit its VAP(R) Cholesterol Test at Internal Medicine 2009 in Philadelphia 2Atherotech to Exhibit its VAP(R) Cholesterol Test at Internal Medicine 2009 in Philadelphia 3Amira Initiates Phase I Clinical Trial of Novel DP2 Antagonist 2AACR 100th Annual Meeting Highlights Superior Ability of InNexus' DXL-Modified Anti-CD20 Antibody to Attach and Kill NHL With Safety Comparable to Approved Antibody Therapies in Preclinical Studies 2AACR 100th Annual Meeting Highlights Superior Ability of InNexus' DXL-Modified Anti-CD20 Antibody to Attach and Kill NHL With Safety Comparable to Approved Antibody Therapies in Preclinical Studies 3
(Date:6/14/2013)... the only ones tending their gardens. , At the ... ants cultivate thriving communities of fungi and bacteria using ... are a source of food and shelter for the ... biofuel production. , "We are interested in the whole ... goes in and is converted to energy for the ...
(Date:6/14/2013)... By identifying a protein that acts as a ... have solved the mystery of why some infants are ... and major deformities of the skin and limbs, while ... little or no sign of the illness, called EEC. ... It is rare in its full-blown form, although individual ...
(Date:6/14/2013)... Data presented at EULAR 2013, the Annual Congress of ... biomarkers could significantly improve diagnosis in rheumatoid arthritis (RA). ... and UH-RA.21 were investigated; as a group they ... both early and seronegative disease, with 36% of ... patients testing positive. , RA is a chronic ...
Breaking Biology News(10 mins):Researchers unearth bioenergy potential in leaf-cutter ant communities 2Researchers unearth bioenergy potential in leaf-cutter ant communities 3CSHL geneticists solve mystery of EEC Syndrome's variable severity in children 2CSHL geneticists solve mystery of EEC Syndrome's variable severity in children 3
... The best place to enjoy a breath of fresh air may ... A team of graduating seniors has created a system for public ... lead to tuberculosis (TB), flu and pneumonia. The CityBusters ... Chen, all seniors have installed a $500 device on a ...
... significantly slow the pace of climate change with practical ... bringing successful Western technologies to the developing world, according ... Foreign Affairs . For the last two ... to make progress. Part of the problem, the ...
... Inc. (NASDAQ: AWRE ), a leading supplier of biometrics ... its first quarter ended March 31, 2012.  Revenues ... of 10% compared to $6.4 million in the same quarter last ... million, or $0.05 per diluted share. These results compared to net ...
Cached Biology News:College students work to sterilize air, kill pathogens on buses 2College students work to sterilize air, kill pathogens on buses 3College students work to sterilize air, kill pathogens on buses 4UCSD researchers: Where international climate policy has failed, grassroots efforts can succeed 2UCSD researchers: Where international climate policy has failed, grassroots efforts can succeed 3UCSD researchers: Where international climate policy has failed, grassroots efforts can succeed 4Aware, Inc. Reports First Quarter 2012 Financial Results 2Aware, Inc. Reports First Quarter 2012 Financial Results 3Aware, Inc. Reports First Quarter 2012 Financial Results 4Aware, Inc. Reports First Quarter 2012 Financial Results 5
Streptomycin sulfate an aminoglycoside used for bacterial selection binds to the small ribosomal subunit and interferes with protein biosynthesis.21H39N7O12)2x3H2SO4Formula weight:...
Adducin beta (C-16)...
This SMAD antibody sampler pack contains 5 Polyclonal ,SMAD antibodies....
Phosphate-Buffered Saline (PBS) 7.4 (1X) liquid...
Biology Products: